



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO & TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: May 13, 2008

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/798,799
Filing Date	3/10/2004
First Named Inventor	Arpita I. MEHTA
Art Unit	1639
Examiner Name	Christopher M. Gross
Attorney Docket Number	085802-0111

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	7,236,888	06-26-2007	Allbritton et al.	
	A2	2003/0124130	07-03-2003	Brown, Robert E.	
	A3	2003/0190689	10-09-2003	Crosby et al.	
	A4	2003/0153014	08-14-2003	Shen et al.	
	A5	2006/0040302	02-23-2006	Botstein et al.	
	A6	2006/0084056	04-20-2006	Harbeck, et al.	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A7	BANKS et al.; The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis—preliminary findings. <i>Electrophoresis</i> , 20:689-700 (1999).	
	A8	BICHSEL et al.; Cancer proteomics: from biomarker discovery to signal pathway profiling. <i>The Cancer Journal</i> , 7(1):69-78 (Jan./Feb. 2001).	
	A9	BRIGHTMAN et al., "4. Computer Simulation of Signal Transduction," <i>Computer Simulation of EGF Signal Transduction</i> , http://bms-mudshark.brookes.ac.uk/frances/fabweb5.htm (accessed on October 29, 2002).	
	A10	BROWN JONES et al.; Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. <i>Proteomics</i> , 2:76-84 (2002).	
	A11	BURKHARDT, "Research Summary – The Role of the Cytoskeleton in T Cell Function," http://cmp.bsd.uchicago.edu/faculty/jBurkhardt.html (accessed on March 6, 2003).	
	A12	CHARBONEAU et al.; Technique Review—Utility of reverse phase protein arrays: applications to signaling pathways and human body arrays. <i>Briefings in Functional Genomics and Proteomics</i> , 1(3):305-315 (Oct. 2002).	
	A13	FRIEDRICH, M.J.; Genomics and proteomics may help clinicians individualize cancer treatment. <i>Journal of American Medical Association</i> , 287(22):2931-2932 (June 12, 2002).	
	A14	IGARASHI et al., "Development of a Cell Signaling Networks Database" <i>Pac Symp Biocomput</i> , 187-97 (1997).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: May 13, 2008 <i>(use as many sheets as necessary)</i>				Application Number	10/798,799
				Filing Date	3/10/2004
				First Named Inventor	Arpita I. MEHTA
				Art Unit	1639
				Examiner Name	Christopher M. Gross
Sheet	2	of	2	Attorney Docket Number	085802-0111

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A15	JAIN, Kewal K.; Recent advances in oncoproteomics. <i>Current Opinion in Molecular Therapeutics</i> , 4(3):2003-209 (2002).	
	A16	KRIEG et al.; Clinical proteomics for cancer biomarker discovery and therapeutic targeting. <i>Tech in Cancer Res & Treatment</i> 1(4): 263-272 (2002)	
	A17	NG, Jocelyn H.; Biomedical applications of protein chips. <i>J. Cell. Mol. Med.</i> , 6(3): 329-340 (2002).	
	A18	ORNSTEIN et al.; Proteomic analysis of laser capture microdissected human prostate cancer and <i>in vitro</i> prostate cell lines. <i>Electrophoresis</i> , 21:2235-2242 (2000).	
	A19	OSIN et al.; Experimental pathology and breast cancer genetics: new technologies. in <i>Adjuvant Therapy of Primary Breast Cancer VI</i> (HJ Senn et al., eds.), 35-48 (1998).	
	A20	SIMONE et al.; Laser capture microdissection: beyond functional genomics to proteomics. <i>Molecular Diagnosis</i> , 5(4):301-307 (2000).	
	A21	SIMPSON et al.; Cancer proteomics: from signaling networks to tumor markers. <i>TRENDS in Biotechnology</i> , 19(10):S40-S48 (Oct. 2001).	
	A22	VON EGGELING et al.; Tissue-specific microdissection coupled with proteinchip® array technologies: applications in cancer research. <i>BioTechniques</i> , 29:1066-1070 (Nov. 2000).	
	A23	WINTERS et al., "Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis," <i>Cancer Res</i> 65(90); 3853-3860 (May 1, 2005).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.